Bausch + Lomb, a leading name in contact lenses and eye care products, was spun off from Bausch Health in 2022. Now, it is reportedly exploring a sale to private equity firms, with Goldman Sachs acting as an advisor to gauge market interest. The sale could potentially provide a significant financial lifeline for Bausch Health, which has been struggling to manage its massive debt, accumulated due to a series of aggressive acquisitions under its previous name, Valeant Pharmaceuticals. Sources familiar with the matter suggest that private equity firms are among the potential buyers, indicating strong interest due to Bausch + Lomb's solid market position and growth potential.